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Fracture riskWe explored the role of transient receptor potential vanilloid 4 (TRPV4) in murine bone metabolism and associ-
ation of TRPV4 gene variants with fractures in humans. Urinary and histomorphometrical analyses demonstrated
reduced osteoclast activity and numbers in male Trpv4−/−mice, which was confirmed in bone marrow-derived
osteoclast cultures. Osteoblasts and bone formation as shown by serum procollagen type 1 amino-terminal
propeptide and histomorphometry, including osteoid surface, osteoblast and osteocyte numbers were not affect-
ed in vivo. Nevertheless, osteoblast differentiation was enhanced in Trpv4−/− bonemarrow cultures. Cortical and
trabecular bonemasswas 20% increased inmale Trpv4−/−mice, compared to sex-matchedwild type (Trpv4+/+)
mice. However, at the same time intracortical porosity was increased and bone matrix mineralization was re-
duced. Together, these lead to a maximum load, stiffness and work to failure of the femoral bone, which were
not different compared to Trpv4+/+ mice, while the bone material was less resistant to stress and less elastic.
The differential impacts on these determinants of bone strength were likely responsible for the lack of any
changes in whole bone strength in the Trpv4−/−mice. None of these skeletal parameters were affected in female
Trpv4−/−mice.
The T-allele of rs1861809 SNP in the TRPV4 locus was associated with a 30% increased risk (95% CI: 1.1–1.6;
p = 0.013) for non-vertebral fracture risk in men, but not in women, in the Rotterdam Study. Meta-analyses
with the population-based LASA study confirmed the association with non-vertebral fractures in men. This
was lost when the non-population-based studies Mr. OS and UFO were included. In conclusion, TRPV4 is a
male-specific regulator of bone metabolism, a determinant of bone strength, and a potential risk predictor for
fractures through regulation of bone matrix mineralization and intra-cortical porosity. This identifies TRPV4 as
a unique sexually dimorphic therapeutic and/or diagnostic candidate for osteoporosis.
© 2013 Elsevier Inc. All rights reserved.Introduction
The bone is an organ undergoing continuous remodeling, requiring a
tight balance between bone resorption (by osteoclasts) and formation
(by osteoblasts). The bone stores 99% of total body Ca2+, making it a
vital player in Ca2+ homeostasis. Members of the transient receptor
potential (TRP) superfamily, predominantly the transient receptorMedicine, Erasmus MC, room
erlands. Tel.: +31107032841;
van der Eerden).
ghts reserved.potential vanilloid channels (TRPVs), have been implicated in both
Ca2+ homeostasis and bonemetabolism.We have demonstrated earlier
in mice that the epithelial Ca2+ channel TRPV5 is crucial for renal Ca2+
reabsorption and for proper bone resorption [1,2]. Moreover, mice
lacking TRPV6 display disturbed intestinal Ca2+ uptake and reduced
bone mass [3–5]. In contrast to TRPV5 and TRPV6, TRPV4 is permeable
to Ca2+ in a non-selectivemanner [6]. TRPV4 responds to awide variety
of stimuli, including hypotonicity, pH, pain, cell swelling,
endocannabinoids and mechanical stretching [7,8]. Recently, it was
shown that activating mutations in the TRPV4 gene leads to several
skeletal phenotypes in humans, including several dysplasias of the
brachyolmia, spondylometaphyseal, Kozlowski and metatropic types
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skeleton but the data obtained are yet inconclusive [11,12]. Although
both studies used the same mouse model, one study examined male
mice while the other study examined female mice. This may implicate
that TRPV4 is a potential driver of skeletal sexual dimorphism such as
differences in size and strength [13].
In order to address this, we studied a head-to-head comparison of
male and female Trpv4−/− mice with respect to the bone phenotype
as well as bone cell differentiation patterns. In addition, we tested ge-
netic variants in the TRPV4 gene locus for association with fracture risk
and bone parameters in human cohorts within a meta-analysis.
Material and methods
Mice, tissue collection and serum/urine analyses
Mice lacking TRPV4 were generated as described extensively [14].
Briefly, cross-breeding of C57Bl/6 TRPV4+/+ and TRPV4−/− mice
resulted in offspring that were heterozygous for TRPV4. This offspring,
bred within the Radboud University Nijmegen Medical Centre animal
facility, was inter-crossed to obtain TRPV4−/−mice. These were subse-
quently inter-crossed and compared to age-matched TRPV4+/+ mice.
Male and female 20-week-old mice, fed ad libitum, were placed in met-
abolic cages to collect 24 hour urine. Next, mice were sacrificed and
serum was collected. Bones were collected for microcomputed tomog-
raphy and histomorphometry (left femurs), 3-point bending tests
(right femurs) and bonemarrow cultures (tibiae). Serum Ca2+was col-
orimetrically determined with a Ca2+ assay kit (Sigma, St. Louis, MO,
USA) according to the manufacturer's description at 595 nm, using a
Bio-Rad microplate reader (Bio-Rad, Hercules, CA, USA). Urinary
deoxypyridinoline (DPD) as a marker for bone resorption was analyzed
using a MetraDPD enzyme immunoassay (Quidel, San Diego, CA, USA).
Serum procollagen type 1 amino-terminal propeptide (P1NP) as a
marker for bone formation was measured with an EIA (IDS, Boldon,
UK). The animal ethics board of the Radboud University Medical Centre
Nijmegen approved all experimental procedures.
Microcomputed tomography (μCT)
Femurs from female andmale TRPV4+/+andTRPV4−/−mice (n = 6)
were scanned at a resolution of 9 μm, using a SkyScan 1172 system
(Bruker MicroCT, Kontich, Belgium). According to guidelines recently
published [15], the following settings were used: X-ray power and
tube current were 40 kV and 0.25 mA, respectively. Beam hardening
(20%) was reduced using a 1 mm aluminium filter, ring-artifacts were
reduced (set at 5), exposure time was 5.9 s and an average of three
pictures was taken at each angle (0.9°) to generate final images. Using
different software packages from Bruker MicroCT (NRecon, CtAn and
Dataviewer), bone microarchitectural parameters were assessed in tra-
becular and cortical bone of all mice (n = 14 for both genotypes). The
trabecular bone parameters trabecular tissue volume, bone volume, tra-
becular volume fraction (BV/TV), trabecular thickness, trabecular num-
ber and trabecular patterning factor (connectivity of trabeculae) were
determined in the distal metaphysis of the femur (scan area 0–4 mm
of proximal femur). In the mid-diaphysis (scan area 4–6.2 mm from
trochanter), cortical volume, cortical thickness, polarmoment of inertia
(MOI; proxy for bone strength) and perimeterwere analyzed. For image
processing, trabecular bone was manually selected and cortical bone
was automatically selected. We used a Hamming filter and global
thresholdingwas applied for segmentation, followedbyusing threshold
levels of 150 (lower) and 194 (higher) for trabecular and levels of 0 and
31 for cortical bone measurements. In addition, trabecular and cortical
bonemineral density (BMD)wasmeasured on basis of calibration scan-
ning, using two phantoms with known density (0.25 mg/cm2 and
0.75 mg/cm2; Bruker MicroCT) under identical conditions as for the fe-
murs (method note from SkyScan provided on website).Bone mechanical properties (3-point bending)
Femurs were stored in phosphate-buffered saline at −20 °C until
further use. Before the 3-point bending test, femurs were scanned
according to the settings mentioned above. The procedure was carried
out as previously described in detail [16]. Briefly, femurs were placed
in a custom made 3-point bending device, with the loading posts
10 mmapart. Mechanical testingwas performed, using a Single Column
Lloyd LRX System (Lloyd Instruments, Fareham, UK). Displacement
(mm) and force (N) were registered. Using the same settings for filtra-
tion, segmentation and binarization asmentioned above in themicroCT
section, the MOI, reflecting the ability of the bone to withstand torsion,
was calculated using CtAnalyzer software (BrukerMicroCT). It is the in-
tegral of the product of the distance between the area of the cortical
bone and the center of gravity on one hand and the cortical bone itself
on the other. This was determined in the μCT scan-derived cross-
section that corresponded to the fracture site resulting from thebending
test. From the resulting displacement to force graphs as well as theMOI
values, ultimate force (N), stiffness (N/mm), work to failure (mJ), ulti-
mate stress (N/mm2) and elastic modulus (GPa) were determined as
described before [17].
Quantitative backscattered electron imaging
The distal half of femoral bone samples were fixed in 70% v/v etha-
nol, dehydrated in ethanol, and embedded in polymethylmethacrylate.
Sample blocks containing grinded and polished surfaces of longitudinal
femoral sections were manufactured. Bone mineralization density dis-
tribution (BMDD) from the trabecular metaphyseal and epiphyseal
as well as from the cortical mid-shaft region was determined using
quantitative backscattered electron imaging (qBEI). A digital scanning
electron microscope (DSM 962, Zeiss, Oberkochen, Germany) operated
at an accelerating voltage of 20 kV, a probe current of 110 pA and
equipped with a four-quadrant semiconductor backscattered electron
detector, was used. Images with spatial resolution of 1 μm per pixel
were acquired for BMDD measurements. This technique is well
established and validated and the details of the method have been
published elsewhere [18,19]. The following BMDDparameterswere cal-
culated 1) CaMean is the weighted average Ca concentration of the
mineralized tissue area, obtained from the integrated area under the
BMDD curve. 2) CaPeak is the peak position of the BMDD histogram
showing the most frequently occurring wt.% Ca of the measured areas.
3) CaWidth is the width at half-maximum of the BMDD histogram
curve indicating the heterogeneity of mineralization and 4) CaLow is
the percentage of bone area with a calcium concentration of less than
17.68 wt.% Ca, which reveals the amount of bone area undergoing pri-
mary mineralization; and CaHigh, the portion of bone area with a calci-
um concentration higher than 25.30 wt.% Ca.
Bone histomorphometry
After excision, femurs were routinely embedded in methyl-
metacrylate as described before [2]. Sections of 6 μm were subjected
to tartrate-resistant acid phosphatase (TRAP) staining. Sections were
deacrylated, hydrated and rinsed in 0.2 M sodium acetate/50 mM
tartaric acid for 5 min. Naphtol AS-MX (0.5 mg/ml) and 1.1 mg/ml
Fast red TR salt (both from Sigma, St. Louis, MO, USA) were added and
incubated for 120 min at 37 °C. Counterstaining was performed with
haematoxylin for 5 s and after air-drying, the sections were embedded
in Permount (Thermo Fischer Scientific, Waltham, MA, USA). For oste-
oid measurements, a von Kossa staining was used. After incubation
with 2% w/v silver nitrate (ICN Biomedicals, Irvine, CA, USA) for 5 min
in daylight, the sections were counterstained with eosin. The sections
were dehydrated and embedded in Entellan (Electron Microscopy
Sciences, Hatfield, PA, USA). Eosin-stained osteoid was specifically visu-
alized, using fluorescent imaging with a 365 nm excitation/420 nm
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were stained with a Goldner staining as described before [20].
Images were taken from the TRAP and Goldner stainings with a
Nikon Eclipse E400 system (Nikon, Lijnden, the Netherlands) and a
Zeiss Axiovert 200 MOT system (Carl Zeiss BV, Jena, Germany) was
used for osteoid stainings. Measurements were performed, using the
software package Bioquant (Version 7.20; Bioquant image analysis cor-
poration, Nashville, Tennessee, USA).
Quantitative PCR analysis (Q-PCR)
RNA isolation, cDNA syntheses, and Q-PCR were performed as de-
scribed previously [21]. Primer and probe sequences and concentrations
used for Q-PCR are listed in Supplementary Table 1.
Bone marrow cultures
Bone marrow cells derived from TRPV4+/+ and TRPV4−/−mice di-
rected towards osteoclasts and osteoblasts were cultured as described
in detail [2,22]. After 6 days of culture, TRAP and coomassie brilliant
blue stainings were used to stain for osteoclasts and resorption pits on
bone slices left behind by osteoclasts, respectively [2]. Osteoclast num-
ber and resorption surface were measured as well as resorption surface
per osteoclast, using the freely available ImageJ software (version 1.41;
http://rsbweb.nih.gov/ij/). Alkaline phosphatase and alizarin red stain-
ing were performed on osteoblast cultures at days 9 and 21 of culture,
respectively, as described earlier [2]. Colony numbers and mineralized
area were quantified using Bioquant.
Genetic association studies in humans
To evaluate the effect of genetic variants in TRPV4 on bone outcomes
we first focused on the Rotterdam Study where deep phenotyping on
bone parameters is available followed by replication assessment of frac-
ture outcomes in three additional studies.
Rotterdam Study
Individuals were derived from the Rotterdam Study (n = 7983), a
single-center prospective population-based cohort studyof determinants
of disabling chronic diseases in the elderly. TheMedical Ethics Committee
of Erasmus University Medical School approved the Rotterdam Study,
and participants provided written informed consent. Both the rationale
and the design of the study have been extensively described previously
[23,24]. In brief, the Rotterdam Study was designed in the mid-1980s as
a response to the demographic changes that were leading to an increase
of the proportion of elderly people in most populations. It was clear that
this would produce a strong rise in elderly people living with diseases, as
most diseases cluster at the end of life, and that to discover the causes of
diseases in the elderly one would have to study the risk factors of those
diseases. The design of the Rotterdam Study is that of a prospective co-
hort study among, initially, 7983 persons living in the well-defined
Ommoord district in the city of Rotterdam in The Netherlands (78% of
10,215 invitees). Theywere all 55 years of age or over and the oldest par-
ticipant at the start was 106 years. The participants were all examined in
some detail at baseline. They were interviewed at home and then had an
extensive set of examinations in a specially built research facility in the
center of their district. These examinations focussed on possible causes
of invalidating diseases in the elderly in a clinically state-of the-art man-
ner, as far as the circumstances allowed. The emphasis was put on imag-
ing (of heart, blood vessels, eyes, skeleton and later brain) and on
collecting bodily fluids that enabled further in-depth molecular and ge-
netic analyses.
Height andweightweremeasured in a standingpositionwearing in-
door clothingwithout shoes. BMIwas computed asweight in kilograms
divided by height in meters squared (kg/m2). During the home inter-
view, female participants were asked to recall their age at menopause,and responses were validated as described previously [25]. Assessment
of vertebral fracture, incident non-vertebral fractures, bone mineral
density (BMD) and bone geometry measurements has been described
in detail previously [26]. In short, fractures where derived from general
practitioner records and validated by two trained physicians. BMD and
hip structural analysis measurements were derived from DXA scans ac-
quired with a GE_Lunar DPX-L scanner.
TRPV4 SNP genotyping
Markers present in the TRPV4 gene region of interest (chromosome
12q24, positions 108,705,277 to 108,755,595) plus 50 kb up- and
downstream of the gene (HapMap release 27, February 2009) were
extracted from Illumina HumanHap 550 K beadchip arrays as described
earlier [27] and included 32 haplotype tagging SNPs. These cover most
of the common genetic variance in the TRPV4 region spanning chromo-
some 12 positions 108623000 to 108801400 and including 78 markers.
Markers were excluded if: a) they deviated significantly from Hardy–
Weinberg equilibrium (p b 1 × 10−4; n = 0), b) the low minor allele
frequency (MAF) was below 5% (n = 2), or c) they had a call rate
b95% (n = 3). The exclusion of 5 tagging markers due to low minor
allele frequency or genotyping call rate did not substantially affect
coverage in the region as only 3 additional markers would be missed.
This resulted in 27 SNPs from the Illumina array in the TRPV4 locus
area available for gene-wide association analyses, using PLINK v1.05
(Supplementary Fig. 1 and Supplementary Table 2). Genomic control
was used to correct for potential population stratification using
genome-wide data [28]. The genomic inflation factor (based on median
chi-squared) ranged between 1.015 (non-vertebral fracture) and 1.049
(femoral neck BMD) across all bone trait analyses providing evidence
against the presence of significant population stratification affecting
the results.
Association analysis
Association of the rs1861809 SNP with bone mineral density (BMD;
femoral neck and lumbar spine BMD) were analyzed. Furthermore,
association with osteoporotic, non-vertebral, fragility, hip, wrist and
vertebral fracture risk as well as hip structural parameters, including
narrow neck (NN) width, NN cortical thickness (Ct.Th), NN cross-
sectional moment of inertia (CSMI) and NN buckling ratio (BR) was
assessed.
Replication cohorts
For replication, men and women from the prospective population-
based cohort study LASA (Longitudinal Aging Study Amsterdam,
n = 904), the prospective study MrOS Sweden (n = 2829) and the
nested case–control study UFO (Umeå Fracture and Osteoporosis,
n = 2807) cohorts were genotyped for rs1861809, the most signifi-
cantly associated marker in the Rotterdam Study using TaqMan Allele
discrimination assay (Applied Biosystems, Nieuwerkerk a/d IJssel, the
Netherlands) and included in the analysis. The Longitudinal Aging
Study Amsterdam (LASA) is an ongoing multidisciplinary cohort study
in older persons. A random sample of men and women aged 55 years
and over, stratified by age, sex, urbanization grade and expected 5-years
mortality rate was drawn from the population register of Amsterdam,
The Netherlands [29]. Follow-up time of the fractures was 6 years.
The Osteoporotic Fractures in Men (MrOS) study is a multicenter,
prospective study including elderly men. Study subjects (men aged
69–80 years) were randomly identified using national population reg-
isters, contacted and asked to participate. Eligible subjects had to be
able to walk without assistance, provide self-reported data, and sign
an informed consent. For this study data from theMrOS Sweden cohort
was used [30]. Assessments of incident fractures have been described
before [31]. The UFO study is a nested case–cohort study investigating
associations between genes, lifestyle and osteoporotic fractures (aver-
age age 65 years of age). The study is based on the prospective and
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initiated to assess risk factors for diabetes and cardiovascular disease
[32,33].
Statistical analyses
If not stated otherwise, SPSS 15.0 (SPSS, Chicago, IL, USA) was used
for the statistical analyses. In all non-genetic experiments values were
expressed as mean ± SEM unless stated otherwise. Differences be-
tween groups were tested for significance using the Student-t-test.
Baseline parameters and bone geometric data from the genetic studies
were expressed asmean ± SD. Differences between groupswere tested
for significance using ANOVA. Values were considered significantly dif-
ferent at p b 0.05. To estimate the risk of fractures, odds ratios with 95%
confidence intervals (95% CI) were calculated using logistic regression
models. Trend analysis assuming an underlying additive genetic
model was done for the presence of zero, one, or two copies of the asso-
ciated allele [34]. Sincewe took only one SNP forward for the replication0.0
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for the mid-diaphyseal cortices for each group are shown (arrows indicate thicker cortices in
presented as means ± SEM. *p b 0.05 versusmale Trpv4+/+ mice (n = 6).studies no multiple testing penalty was applied, hence p-values b0.05
were considered statistically significant.Results
Bone phenotype of male and female Trpv4−/−mice
μCT analyses demonstrated a positive effect on bone mass following
TRPV4 deficiency in male but not in female mice. Male Trpv4−/− mice
displayed increased femoral trabecular (Figs. 1A and B) and cortical
(Figs. 1C–E) bone mass compared to female Trpv4+/+ mice. Femoral
bone size was also increased in male Trpv4−/− mice as exemplified
by larger femoral head volume, diaphyseal volume, perimeter
(Figs. 1F–H, respectively) and femoral length (Supplementary
Table 3). In females, all parameters described above were unaffected.
A summary of these and additional μCT parameters are listed in Supple-
mentary Table 3.0
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DPD analysis showed reduced bone resorption in male Trpv4−/− mice
compared to Trpv4+/+ (Fig. 2A). Histomorphometrical analyses of
TRAP staining on bone sections confirmed this (Fig. 2B). In femurs
from male Trpv4−/− mice, osteoclast number (Fig. 2C) and surface
area resorbed (data not shown) was significantly reduced. In contrast,
no differences in bone resorption and osteoclast number were observed
between the female Trpv4+/+ and Trpv4−/−mice (Fig. 2A and data not
shown).
Bone marrow-derived osteoclast cultures supported the in vivo ob-
servations that osteoclast number and resorption is disturbed in male
Trpv4−/− but not female mice. Fewer osteoclasts developed from male
Trpv4−/− bone marrow compared to that of Trpv4+/+ mice (Fig. 2D),
which is paralleled by a significantly reduced resorption surface area
(Fig. 2E). Resorption surface per osteoclast analyses demonstrated that
osteoclast activity from Trpv4−/− cultures is impaired (Fig. 2F). None
of these differences were found in female Trpv4−/− bone marrow-
derived osteoclast cultures (e.g. osteoclast numbers: 35.1 ± 3.3 versus
29.6 ± 5.4, p = 0.44 for female Trpv4+/+ versus Trpv4−/−mice).
When osteoclast–osteoblast coupling during bone remodeling is in-
tact, reduced osteoclast function should lead to attenuated osteoblast
activity. In male Trpv4−/−mice, bone formation was unaffected despite
reduced bone resorption as shown by serum P1NP analyses (Fig. 3A).
This is supported by histomorphometrical assessment of bone sections
showing no differences in number of osteoblast lining trabecular bone
(Fig. 3B), percentage osteoid surface (Fig. 3C) and osteocytes in cortices
(Fig. 3D) between male Trpv4+/+ and Trpv4−/−mice.
While the in vivo findings strongly suggest that osteoblast differenti-
ation and function remain unaffected in Trpv4−/−mice, osteoblast differ-
entiation was enhanced in bone marrow cultures. Trpv4−/− osteoblast
cultures showed a significant increase in the number of alkaline phos-
phatase positive colonies (Fig. 3E) as well as elevated Ca2+ deposition,
although this did not reach significance (Fig. 3F). Colony size was not af-
fected in cultures from male Trpv4−/− mice (0.10 ± 0.02 mm versus0
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Resistance to stress and elastic modulus is reduced in male Trpv4−/−mice
To assess whether increased bone mass led to improved bone
strength, 3-point bending tests were performed on femurs from male
and female Trpv4+/+ and Trpv4−/− mice (Figs. 4A–E). Maximum load,
stiffness and work to failure were not different between Trpv4+/+ and
Trpv4−/− mice (Figs. 4A–C). Interestingly, the femurs from Trpv4−/−
mice were less resistant to stress (Fig. 4D) and less elastic (Fig. 4E).
However, polar moment of inertia was increased in the Trpv4−/−mice
at the site of fracture (Fig. 4F). None of these differences were seen in
bones from female mice (e.g. stress: 87.6 ± 2.9 GPa versus 75.0 ±
3.4 GPa, p = 0.31 for female Trpv4+/+ versus Trpv4−/−mice).
We assessed cortical porosity by quantifying the holes appearing in
the cortical bone (Fig. 4G–H). Cortical porosity was more than doubled
in themale Trpv4−/−mice compared to Trpv4+/+mice (Fig. 4I and Sup-
plementary Table. 3). The diameter of these holes varied between 40
and 160 μm. Increased cortical porosity was not observed in the female
mice (Supplementary Table 3). Bonemineral density of the femoral tra-
becular and cortical compartmentwas unaltered and slightly but signif-
icantly increased, respectively, in the Trpv4−/−mice (Figs. 4J–K).
Finally, we measured bone mineralization density distribution at
three positions in femurs of the male Trpv4+/+ and Trpv4−/− mice
(Fig. 5A). The bone matrix of Trpv4−/− mice was significantly lower
mineralized compared to Trpv4+/+ mice at all skeletal sites analyzed
(metaphysis, epiphysis and corticalis) as shown by the significant re-
duction of CaMean, CaPeak and CaHigh (Figs. 5B, C and D). The width
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448 B.C.J. van der Eerden et al. / Bone 57 (2013) 443–454heterogeneity in mineralization is not different between the genotypes
(Fig. 5E). The fraction of lowlymineralized bone areas (CaLow), i.e. areas
of ongoing bone formation (primary mineralization), in the Trpv4−/−
mice is not different from that in Trpv4+/+ mice (Fig. 5F).
Human genetic association studies on TRPV4 and fracture risk
We investigated the contribution of TRPV4 to bone phenotypes
in humans by studying the association of genetic variants in the
TRPV4 gene locus with skeletal phenotypes and fracture risk. Baseline
characteristics for the Rotterdam Study population are provided in
Supplementary Table 4. Using PLINK software, we tested 27 tagging sin-
gle nucleotide polymorphisms (SNPs) in the TRPV4 locus for potential
association with bone mineral density (BMD), hip geometry and
fracture risk in the Rotterdam Study (Supplementary Table 2 and
Supplementary Fig. 1) as a discovery cohort. Two intronic tagging
SNPs located between exons 2 and 3 of the TRPV4 gene (rs10850783,
C to A, minor allele frequency = 27.4% and rs1861809, C to T, 27.3%;Supplementary Table 2 and Supplementary Fig. 1) were found to be as-
sociated with osteoporotic fractures (p = 0.002). These SNPs were in
complete linkage disequilibrium and so rs1861809 was chosen for fur-
ther analyses. No association was observed for rs1861809 with femoral
neck and lumbar spine BMD in either men or women (Supplementary
Table 5). The hip bone geometric parameters' narrow neck (NN)
width and NN cross-sectional moment of inertia (CSMI) were signifi-
cantly higher in men with the TT genotype (p = 0.006 and p = 0.02,
respectively), but this effect was not observed in women (p = 0.2 and
0.14, respectively; Supplementary Table 5). NN cortical thickness
(Ct.Th) and buckling ratio (BR)were not significantly different between
the genotypes in either men or women (Supplementary Table 5).
Risk of osteoporotic fractures was 1.9 times higher in men homozy-
gous for the T-allele of rs1861809 (Table 1). Men had a 40% increased
risk for osteoporotic fractures per T-risk allele (95% CI = 1.1–1.7, p =
0.005). For fragility and hip fractures the risk was 1.6 times (95%
CI = 1.1–2.2, p = 0.005; and 1.1–2.4, p = 0.011, respectively) higher
per risk allele, while for wrist fractures the risk was 2 times (95%
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449B.C.J. van der Eerden et al. / Bone 57 (2013) 443–454CI = 1.1–3.5, p = 0.014) higher per risk allele. In contrast to men, no
associationwith any type of fracture was observed for women (Table 1).
Next, we sought replication of our genetic associations in other
cohorts, including LASA,MrOS and UFO (baseline characteristics in Sup-
plementary Tables 6 and 7). Inmen from the LASA study the same trend
for increased risk for osteoporotic fracture was observed in carriers of
the T-allele (OR = 1.5, 95% CI 0.9–2.5, p = 0.11) (Supplementary
Table 8). Meta-analyses of the Rotterdam and LASA studies togetherwere consistent with a 40% increase in risk for osteoporotic fracture
(OR = 1.4, CI = 1.1–1.7, p = 0.001) per risk allele (Fig. 6). However,
in the Swedish MrOS and UFO studies, no evidence for association
with osteoporotic fracture risk was observed in either study. (Supple-
mentary Table 8 and Fig. 6). In the meta-analysis, including all four co-
horts, the association of the polymorphism with osteoporotic fracture
was lost for men (OR = 1.1, CI = 1.0–1.3, p = 0.167; Fig. 6). As
expected, for women the association with osteoporotic fractures
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any signification associations found for other types of fractures (data
not shown).
Discussion
In this multidisciplinary study, using Trpv4−/−mice, ex vivo cell bio-
logical analyses and genetic association data from human cohorts, we
demonstrate that TRPV4 is an important sexually dimorphic factor forTable 1
Fracture risks in the Rotterdam Study population for rs1861809.
Men
Trait CC CT TT
Non-vertebral fractures
No. fractures/total no. 46/675 113/1176 54/498
(%) (6.8%) (16.7%) (20.0%)
OR (95% CI) 1 1.5 (1.0–2.1) 1.7 (1.1–2.5)
Osteoporotic fractures
No. fractures/total no. 41/675 89/1176 53/498
(%) (6.1%) (7.6%) (10.6%)
OR (95% CI) 1 1.3 (0.9–1.9) 1.9 (1.2–2.8)
Fragility fractures
No. fractures/total no. 15/675 41/1176 26/498
(%) (2.2%) (3.5%) (5.2%)
OR (95% CI) 1 1.6 (0.9–3.0) 2.5 (1.3–4.8)
Hip fractures
No. fractures/total no. 11/675 27/1176 20/498
(%) (1.6%) (2.2%) (4.0%)
OR (95% CI) 1 1.4 (0.7–2.9) 2.6 (1.2–5.6)
Wrist fractures
No. fractures/total no. 5/675 10/1176 12/498
(%) (0.7%) (0.9%) (2.4%)
OR (95% CI) 1 1.2 (0.4–3.4) 3.3 (1.2–9.5)
Data are presented as number of fractures as a percentage of total for each genotype, stratified b
were adjusted for gender, age, height and weight. Trend values represent p-value for an allele-determining bone strength, with potentially clinically relevant implica-
tions at the population level.
Male Trpv4−/− mice display reduced osteoclast function and
osteoclast–osteoblast uncoupling
TRPV4 deficiency leads to an increased bone mass phenotype in
male, but not in female mice. This predominantly results from de-
creased osteoclast formation/differentiation and activity, which hasWomen
Trend CC CT TT Trend
0.013 207/951 331/1672 152/703 0.785
(21.7%) (19.8%) (21.7%)
1 0.9 (0.7–1.1) 1.0 (0.8–1.3)
199/951 319/1672 145/703 0.983
0.005 (20.9%) (19.1%) (20.7%)
1 0.9 (0.7–1.1) 1.0 (0.8–1.3)
84/951 130/1672 63/703 0.968
0.005 (8.8%) (7.8%) (9.0%)
1 0.9 (0.6–1.2) 1.0 (0.7–1.5)
52/951 83/1672 39/703 0.886
0.011 (5.5%) (5.0%) (5.6%)
1 0.9 (0.6–1.3) 1.1 (0.7–1.6)
0.014 62/951 101/1672 47/703 0.942
(6.5%) (6.0%) (6.7%)
1 0.9 (0.7–1.3) 1.0 (0.7–1.5)
y gender. Odds ratios (OR) are depictedwith 95% confidence intervals (CI). All associations
dose effect.
Fig. 6.Meta-analysis for osteoporotic fracture risk. Forest plot of the group-wise genotypemeta-analysis for osteoporotic fracture risk inmenacross studies for rs1861809. Provided are the
odds ratios for TT versus CC genotype in males and females from the Rotterdam Study, LASA, MrOS Sweden and UFO. All associations were adjusted for age, height and weight.
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osteoblast–osteoclast coupling in bone turnover it was anticipated
that impaired osteoclast differentiation would lead to reduced osteo-
blast differentiation. However, bone formation is not affected in the
male Trpv4−/−mice in this study, although it is enhanced in ex vivo cul-
tures. This implies that TRPV4 acts indirectly in vivo, throughmesenchy-
mal stem cells (MSCs) and limits their differentiation into osteoblasts.
TRPV4 is also abundantly expressed on osteoblasts, which suggests a di-
rect effect; themechanism throughwhich TRPV4 acts on osteoblasts re-
mains elusive. In contrast to our data, it was demonstrated very recently
that bonemarrow-derivedMSCs from Trpv4−/−mice actually were less
osteogenic compared towild typeMSCs,whereas the oppositewas seen
for adipose tissue-derived MSCs [36]. However, these findings are diffi-
cult to directly correlatewith our data, due to themethodological differ-
ences in cell collection (cell sorting), additional passaging of the cells
before osteogenic differentiation and culturing under hypoxic condi-
tions, which has been shown to have profound effects on osteogenic dif-
ferentiation [37]. The reduced bone resorption (DPD as a marker)
together with the unchanged bone formation marker (P1NP) demon-
strates osteoblast–osteoclast uncoupling following TPRV4 deficiency in
malemice only. A summary of the results and amore detailed reasoning
for this conclusion is shown in panels 1–6 in Fig. 7. Based on the current
data we propose that lack of TPRV4 in male mice, but not female mice,
enhances osteoblast development via an osteoblast-intrinsic mecha-
nism (observed: in vitro enhanced osteoblast development; panel 5) that
(partially) overrules the in vivo osteoclast–osteoblast coupling signal
(observed: in vivo unchanged bone formation; panels 4 and 6) that
would have led to reduced osteoblast activity as a consequence of the
reduced osteoclast activity and bone resorption (observed: in vivo and
in vitro; panels 2 and 6). Overall, these analyses demonstrate a clear
sex-specific effect of TRPV4 on bone phenotype, which is due to im-
paired osteoclast function and disturbed coupling between osteoclasts
and osteoblasts.
Male Trpv4−/− mice have increased cortical porosity and reduced matrix
mineralization
Despite reduced osteoclast activity, male Trpv4−/− mice have in-
creased cortical porosity, an important predictor in diagnosing osteoporo-
sis [38]. In fact, non-vertebral fractures at predominantly cortical sitesaccount for 80% of all fracture age-related osteoporosis [39]. In several
mouse models where osteoclast function is increased, such as one
where the PTH receptor is constitutively active, or one that overexpresses
cathepsin K, intracortical porosity is abundant [40,41]. In addition, mice
lacking the gastrin receptor Cckbr associated with hypochlorhydria also
suffer from increased cortical porosity due to low intestinal Ca2+ absorp-
tion and secondary hyperparathyroidism [42]. However, cortical porosity
maywell arise from insufficient bone remodeling during bone develop-
ment. For bone remodeling, osteoclast activity is required, which is
defective in themale Trpv4−/−mice. An alternative, intriguing explana-
tion is the process of osteocytic osteolysis, a mechanism by which oste-
ocytes are able to resorb their surrounding perilacunar extracellular
matrix, which may lead to intracortical porosity (Reviewed in:
[43,44]). Although osteocyte densitywas not altered in femoral cortices
of ourmale Trpv4−/−mice (Fig. 3D) the presence of osteocytic osteolysis
remains to be established. However, to achieve this yet robust means to
quantitatively assess osteocytic osteolysis need to be developed.
The reduction in matrix mineralization in Trpv4−/− mice demon-
strates a role for this ion channel in mineralization of bone. The mainte-
nance of cortical bone strength observed in Trpv4−/−malemice despite
an increased cortical porosity and the observed reduced bone matrix
mineralization can be best explained by a compensatory effect of the in-
crease in bone mass, as reflected by an enhanced moment of inertia. In
general, reduced bone matrix mineralization causes a lower ultimate
stress and elastic modulus and increased intracortical porosity weakens
additionally themechanical competence of whole cortical bone [45,46].
Interestingly, BMD was only slightly increased in these mice. However,
taken into account, that a change in BMD has to be considered as the
sum of changes in bone volume and bone matrix mineralization [47],
it seems that the extent of the increase in bone volume fairly compen-
sated for the increase in porosity and the reduction in bonematrix min-
eralization in these Trpv4−/−mice.
The T-allele of rs1861809 is associated with increased fracture risk in men
In the Rotterdam Study we observed that the rs1861809 polymor-
phism between exons 2 and 3 of TRPV4 harbors BMD-independent
sex-specific effects on osteoporotic fracture risk. Our study and others
claim that it is crucial to studymen andwomen independently to deter-
mine sex-specific genetic factors that contribute to osteoporosis risk
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452 B.C.J. van der Eerden et al. / Bone 57 (2013) 443–454[48]. Similarly, it has been proposed that including bone structural pa-
rameters can aid the assessment of fracture risk [49–51]. Nevertheless,
performing sex-stratified analysis is a limiting approach resulting in a
lower power setting.
Male-specific skeletal findings arising from Trpv4−/− mice and the
ex vivo cell biology analyses were in line with those observed in men
from the Rotterdam Study. In addition, including the LASA study (also
of Dutch ancestry) resulted in a consistent, albeit smaller, effect esti-
mate, which is most probably a natural consequence of smaller sample
size and less power. The association in two additional studies of Swedish
origin and lower number of fracture cases did not follow the same trend
observed in the studies of Dutch origin. We do not foresee population-
specific effects as allele frequencies of the Rotterdam and LASA studies
were similar to those observed in theMrOS Sweden cohort. We did ob-
serve different allele frequencies in the UFO cohort as compared to the
prospective nature of the other three cohorts,whichmay be attributable
to its case/cohort design. Indeed, having a set of controls enriched with
osteoporotic subjects may be an explanation for the observed deviant
allele frequencies and also a potential explanation for the lack of associ-
ation in the UFO cohort. We did not see an effect on BMD but a lower
BMD may potentially reflect an enriched set of controls with fracture.
Even though the male-specific effect of variants in TRPV4 in relation to
fracture was observed in populations of Dutch origin, further scrutiny
of these associations in additional prospective cohorts is warranted to
confirm potential translation of the effects seen in mice to men.
TRPV4 has been shown to respond to alterations in osmolarity as
well as to hypotonicity (reviewed in Cohen et al., 2007). Of interest,
we previously demonstrated in the Rotterdam Study that patients
with hyponatremia had a 40% increased risk of getting a non-vertebral
fracture [52]. In concordance, others showed a role for hyponatremia
in osteoporosis,most likely through activation of osteoclasts [53,54]. Fu-
ture work should point out whether TRPV4 may be a gateway between
hyponatremia and fracture risk in the elderly.Phenotype consistencies and inconsistencies across species
The consistency between the genetic association data in the
Rotterdam and LASA Studies and the findings in the Trpv4−/− mice –
that bone strength is affected in males but not in females – is striking.
An explanation for increased fracture risk in men despite an increase
in bone mass may reside in reduced bone matrix mineralization and/
or increased cortical porosity, as was shown in themale mice. Although
there are studies describing the assessment of cortical porosity in the
distal radius [38], we currently have no bone matrix mineralization
and cortical porosity data from the Rotterdam Study to corroborate
this hypothesis at the population level. Interestingly, increased mid-
pubertal cortical thickness is associated with an increase in forearm
fractures but also with elevated cortical porosity [55], which is more
pronounced in boys than in girls [56]. These processes evolve from
endocortical bone resorption, most likely due to excess Ca2+ require-
ments in the growing adolescent [57,58]. It is tempting to speculate
that this transient ‘weakness’ of the long bones, in combination with
DNA variations in the TRPV4 locus may lead to more permanent alter-
ations in bone structure and/or composition resulting in an increased
fracture risk for elderlymen. There is recent supporting data that reduc-
tion in bone matrix mineralization can contribute to the increased frac-
ture risk in men [59,60].
Childhood fractures may actually better reflect the porosity pheno-
type we observe in the male Trpv4−/−mice, being bone growth related
rather than bone loss related, which occurs in the human aging cohorts
that we assessed in this study. Although fracture incidence seems to
show a bimodal patternwith an increased fracture incidence during pu-
berty, the incidence is still very low compared to that of the elderly pop-
ulation and studies will lack power. With recently initiated population
studies such as the Generation R cohort focusing on children from
birth to adulthood [61], we may be able to study childhood fractures
in the forthcoming years.
453B.C.J. van der Eerden et al. / Bone 57 (2013) 443–454Dominant mutations in the TRPV4 gene lead to a comprehensive
family of bone dysplasia's, ranging from lethal metatotropic dysplasia to
familial arthropathy with brachydactyly [62]. The range and severity
of the skeletal conditions together with the knowledge that a single
mutation in the TRPV4 gene leads to different dysplasias, suggests modu-
lation by other parts of the genome. Despite the humanmutations,which
so far are all dominant and activating of nature, ablation of the whole
gene inmurine studies (thereby inactivating the gene) displays a surpris-
ingly mild skeletal phenotype ([11] and our data). Potentially, activating
TRPV4 function by introducing the mutations leading to the various
human bone dysplasias in a murine setting will phenocopy what we
see in man but this requires extensive mouse genetic approaches.
TRPV4 deficiency is sexually dimorphic
The current study demonstrates a role for TRPV4 in explaining sexu-
al dimorphism in bone metabolism and maintenance of bone strength.
The underlying mechanism is unclear and currently purely speculative
but other examples of a gender-specific bone phenotype have been de-
scribed, for example in myeloid-specifically ablated leptin receptor
knockout mice [63]. A role for sex steroid hormones such as androgens
or estrogens seems logical but there is no data to support an interaction
with TRPV4. It has been reported that TRPV4 is expressed in the testes of
male rats [6,64] but a relation with sex steroid production has not been
shown. Although we cannot fully explain the current sex-specific find-
ings in the Trpv4−/− animals we did find an induction of TRPV4 mRNA
expression by 17β-estradiol in cultured osteoblasts from male, but not
female mice, suggesting a difference in sensitivity to sex steroids be-
tween males and females. It is worth mentioning that although sex
was not mentioned in the majority of the reports describing a pheno-
type in Trpv4−/− mice, the ones that did, actually used male mice in
their studies [11,65,66]. Of interest, in a recent review it was stated
that sex differences also occur in the absence of hormonal changes
through sex chromosome-mediated epigenetic regulation of autosomal
chromosomes, such asDNAmethylation and histonemodifications [67].
Conclusion
In conclusion, TRPV4 is a male-specific determinant of bone
strength. TRPV4 influences bone by uncoupling of osteoclast and osteo-
blast activity and increase in bonemass in a sexually dimorphicmanner.
In addition, TRPV4 plays a role in bone matrix mineralization, which is
reduced, and together with enhanced cortical porosity, may lead to re-
duced elasticity of bone. The increased bone mass and moment of iner-
tia observed in themale Trpv4−/−mice seem to preserve bone strength,
but this compensationmechanismmay be lost during aging, potentially
leading to reduced bone strength and fracture risk. Finally, the human
genetic association analyses, which support a role of TRPV4 in male
but not female osteoporosis, need to be replicated and verified.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bone.2013.09.017.
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